Moderna
The mRNA-platform biotech that rose with its COVID vaccine; now betting the platform on cancer and rare disease.
Coverage of Moderna is holding steady : 6 signals on the latest tracked day, down 45% from its three-week baseline of 11, across 3 domains (unchanged from a week ago). That makes it the #304 most-covered of the 348 concerns we track.
What’s changed
7 of the last 7 tracked days ran below the three-week baseline — a sustained cooling, not a one-day dip.
- Moderna Rises 6% Despite GSK Moving Rival mRNA Flu Vaccine to Phase III · 24/7 Wall St. · 2026-09-02
- ‘This Breakup Saved You Far More Than Moderna Ever Could’: Orman to Woman Dumped After 180% Spike · 24/7 Wall St. · 2026-08-30
- Moderna raises $2.6B to support cancer work; FDA clears updated COVID vaccines · BioPharma Dive — Latest News · 2026-08-29
- BioNTech Tumbles 8% as Colorectal Cancer Vaccine Trial Fails, Moderna Drops 6%, Pfizer Holds Flat · 24/7 Wall St. · 2026-08-28
- What’s in Merck and Moderna’s cancer vaccine algorithm? · STAT News — All Content · 2026-08-27
- STAT+: The mystery of Moderna’s magic algorithm · STAT News — All Content · 2026-08-27
What the reporting says
Across 35 tracked stories from 20 outlets, reporting on Moderna most often describes regulatory approvals (4), military action (1), launches or releases (1), elections (1).
It shows up alongside Merck (21), AI (8), Immunotherapy (13), Covid (11), FDA (11), Covid 19 (8).
Two steps out: Abstract (through Immunotherapy, 13 shared stories on the weaker link); Astrazeneca (through Merck, 13 shared stories on the weaker link); Braf (through Immunotherapy, 13 shared stories on the weaker link); Chen (through Immunotherapy, 13 shared stories on the weaker link).
Tracked since Jul 8, with coverage on 15 separate days — concentrated in Biotech Pharma and Auto.